Ibogaine Clinical Trials Framework

Current understanding

Michigan House Bill 6020 of the 103rd Legislature proposes to amend sec. 7212 of the Public Health Code (1978 PA 368, MCL 333.7212) and add new sections 2222, 2222a, and 2222b to establish a legal framework enabling participation in ibogaine clinical trials. Ibogaine is a Schedule I controlled substance, and the bill would carve out research access for clinical trial participants and investigators. The bill has been introduced.

Evidence log

• 2026-05-21 — Health: research; participation in ibogaine clinical trials; provide for. Amends sec. 7212 of 1978 PA 368 (MCL 333.7212) & adds secs. 2222, 2222a & 2222b.: cross-connection with controlled-substance-scheduling: HB 6020 modifies the controlled substance schedule statute (MCL 333.7212) to enable ibogaine (Schedule I) clinical trial access, linking the new research framework directly to Michigan’s controlled substance scheduling regime. (novelty: 3)

Open questions

Related